Showing 8311-8320 of 18151 results for "".
- Algorithm Helps Doctors Identify More Aggressive Types of Basal Cell Carcinomahttps://reachmd.com/news/algorithm-helps-doctors-identify-more-aggressive-types-of-basal-cell-carcinoma/2467806/A newly developed algorithm can assist healthcare professionals in identifying patients with a highly aggressive form of basal cell carcinoma (BCC) on the face. Accurately recognizing more high-risk BCCs allows patients to receive the most effectiv
- Researchers Identify Distinct Sleep Types and Their Impact on Long-Term Healthhttps://reachmd.com/news/researchers-identify-distinct-sleep-types-and-their-impact-on-long-term-health/2462298/UNIVERSITY PARK, Pa. — Poor sleep habits are strongly associated with long-term chronic health conditions, according to decades of research. To better understand this relationship, a team led by researchers in Penn State’s College of Health and Human Development identified four distinct
- Emerging Biomarkers in Diabetic Retinopathy: The Potential Role of Pentraxin 3 and Stress Hyperglycemia Ratiohttps://reachmd.com/news/emerging-biomarkers-in-diabetic-retinopathy-the-potential-role-of-pentraxin-3-and-stress-hyperglycemia-ratio/2475732/Subclinical microvascular injury in patients with diabetes often goes unnoticed until vision is compromised, underscoring an urgent need for diagnostic tools that detect early retinal changes and preserve quality of life through timely i
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://reachmd.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474516/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick skin types
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://reachmd.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2475350/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick skin types
- New AI Tool Accurately Detects 6 Different Cancer Types on Whole-Body PET/CT Scanshttps://reachmd.com/news/new-ai-tool-accurately-detects-6-different-cancer-types-on-whole-body-petct-scans/2467008/June 10, 2024 Toronto, Ontario—A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. By automatically q
- Could a Common Diabetes Drug Ease Knee Osteoarthritis Pain—and Delay Surgery?https://reachmd.com/news/drug-repurposing-diabetes-medication-for-managing-knee-osteoarthritis-pain/2474341/In an era where repurposing familiar drugs has become a promising frontier in medicine, metformin—a stalwart in type 2 diabetes care—is stepping into an unexpected new role. Recent clinical trials suggest that this decades-old medication may significantly reduce kn
- Integrating Social Determinants and Therapeutic Innovations in Diabetes Managementhttps://reachmd.com/news/integrating-social-determinants-and-therapeutic-innovations-in-diabetes-management/2476032/Diabetes management is as much about understanding social contexts as it is about leveraging the latest medical advancements. Unpacking these layers is critical in shaping effective and equitable healthcare strategies. Social determinants like neighborhood deprivation exert a measura
- Diabetes Prevention and Education: Lifestyle Interventions in Focushttps://reachmd.com/news/diabetes-prevention-and-education-lifestyle-interventions-in-focus/2474367/With rising rates of diabetes, prediabetes, and obesity, healthcare professionals are leveraging educational programs that combine nutritional guidance with structured physical activity to halt disease progression and empower patients. Overview
- GLP-1 Receptor Agonists Linked to Lower Risk of Early-Onset Colorectal Cancer in Diabetic Patientshttps://reachmd.com/news/glp-1-receptor-agonists-linked-to-lower-risk-of-early-onset-colorectal-cancer-in-diabetic-patients/2468569/In a promising development for cancer prevention, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used in diabetes management, have been linked to a reduced risk of early-onset colorectal cancer (EO-CRC) in patients under 50 with type 2 diabetes. These findings, presented at the r